Comparison of the mesodermal differentiation potential between embryonic stem cells and scalable induced pluripotent stem cells

Author:

Tsai En-Tung12,Tseng Huan-Chin23,Liu Yu-Hao23,Wu You-Ren4,Peng Shih-Yuan23,Lai Wei-Yi23,Lin Yi-Ying23,Chen Shih-Pin1256,Chiou Shih-Hwa1274,Yang Yi-Ping23,Chien Yueh23

Affiliation:

1. Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC

2. Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

3. School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC

4. Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, ROC

5. Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

6. Brain Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC

7. Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

Abstract

Background: Mesenchymal stem cells (MSCs) have promising potential in clinical application whereas their limited amount and sources hinder their bioavailability. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have become prominent options in regenerative medicine as both possess the ability to differentiate into MSCs. Methods: Recently, our research team has successfully developed human leukocyte antigen (HLA)-homozygous iPSC cell lines with high immune compatibility, covering 13.5% of the Taiwanese population. As we deepen our understanding of the differences between these ESCs and HLA-homozygous iPSCs, our study focused on morphological observations and flow cytometry analysis of specific surface marker proteins during the differentiation of ESCs and iPSCs into MSCs. Results: The results showed no significant differences between the two pluripotent stem cells, and both of them demonstrated the equivalent ability to further differentiate into adipose, cartilage, and bone cells. Conclusion: Our research revealed that these iPSCs with high immune compatibility exhibit the same differentiation potential as ESCs, enhancing the future applicability of highly immune-compatible iPSCs.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3